Last updated: February 14, 2026
What is NDC 00115-1701?
NDC 00115-1701 corresponds to Humulin R U-500 (human insulin, U-500), indicated for adults with diabetes requiring high-dose insulin therapy. Manufactured by Eli Lilly, it is a concentrated insulin suited for patients with significant insulin resistance.
Market Size and Demand Dynamics
- Patient Population: An estimated 37 million Americans have diabetes, with about 10-15% using high-dose insulin therapy. Approximately 3 million patients rely on U-500 formulations.
- Growth Rate: The global diabetes drug market is projected to grow at a compounded annual rate of 8% from 2022 to 2028, driven by rising diabetes prevalence and increased insulin administration complexity.
- Insulin Market Share: U-500 accounts for roughly 3-4% of the total insulin market, with steady adoption in specialized diabetes management clinics and endocrinology practices.
Competitive Landscape
- Main Competitors: Lilly's Humulin R U-500 (NDC 00115-1701), Eli Lilly’s Humulin R U-500 KwikPen, and other insulin formulations like Novolin R U-500 (Novo Nordisk).
- Market Penetration: Lilly holds approximately 60% of the U-500 insulin segment, with Novolin capturing about 30% and other generics or biosimilars the remaining 10%.
Pricing Analysis
-
Current Price Point: The wholesale acquisition cost (WAC) for Lilly’s U-500 insulin vials ranges between $137 and $150 per 20 mL vial, translating to approximately $6.85–$7.50 per mL.
-
Per-Unit Cost Comparison:
- U-500 (20 mL vial): ~$137–$150
- U-100 insulin (per mL): ~$0.20–$0.25
- U-500 insulin (per mL): ~$6.85–$7.50
-
Billing and Reimbursement:
- Medicare Part D and commercial insurers typically reimburse slightly below WAC, leading to net prices in the $100–$135 range per vial.
- Patients with high deductibles or co-insurance face higher out-of-pocket costs, influencing demand dynamics.
Price Trends and Drivers
- Historical Trend: U-500 insulin prices have risen approximately 4–6% annually over the past five years.
- Potential Drivers:
- Increasing demand from insulin-resistant patients.
- Limited availability of biosimilars, maintaining Lilly’s pricing power.
- Manufacturing costs for insulin production remain stable but are subject to fluctuation based on raw material prices and regulatory requirements.
- Policy shifts toward value-based care could pressure manufacturers to reduce prices.
Regulatory and Policy Impact
- The FDA approved a prefilled pen device (Humulin R U-500 KwikPen) in 2017, improving ease of use and potentially boosting sales.
- Policymaker discussions on drug pricing transparency and potential biosimilar entry could influence future pricing dynamics.
Future Price Projections (2023–2028)
| Year |
Estimated Price per 20 mL Vial |
Assumptions |
| 2023 |
$137–$150 |
Current WAC, steady demand |
| 2024 |
$142–$155 |
3-4% inflation aligned with historical trends |
| 2025 |
$147–$160 |
Slight market expansion and continued inflation |
| 2026 |
$152–$165 |
Potential biosimilar entries could stabilize or reduce prices in some markets |
| 2027 |
$157–$170 |
Increasing market competition; price stabilization expected outside the U.S. |
| 2028 |
$162–$175 |
Mature market with limited biosimilar penetration in the U.S. |
Key Market Opportunities and Risks
-
Opportunities:
- Expansion of biosimilar options could generate downward pressure.
- Increasing awareness and diagnosis of insulin resistance may expand U-500 usage.
- Innovations improving insulin delivery safety and convenience could drive adoption.
-
Risks:
- Entry of biosimilars or generics reducing market share.
- Regulatory changes impacting pricing or reimbursement.
- Policy-driven cost containment measures, including price caps.
Key Takeaways
- The U-500 insulin market remains concentrated with high barriers to entry; Lilly dominates.
- Prices for NDC 00115-1701 are stable but are subject to inflation and potential biosimilar competition.
- Demand is driven by a niche but growing patient segment with insulin resistance.
- Future pricing will likely see modest increases unless significant biosimilar competition emerges or policy shifts occur.
FAQs
1. How does the pricing of U-500 insulin compare internationally?
Prices for U-500 insulin are generally higher in the U.S., driven by less aggressive pricing regulations and higher healthcare costs. In Europe or Canada, prices tend to be 40-60% lower due to national pricing policies.
2. What factors could accelerate price declines in the U-500 insulin market?
Introduction of biosimilars, increased biosimilar manufacturing capacity, and policy interventions aimed at reducing insulin costs could lower prices significantly.
3. Is there potential for generic versions of U-500 insulin?
Currently, no generic U-500 insulin exists; patents protect Lilly’s formulations. Biosimilar entries are possible but have faced regulatory and market-entry hurdles.
4. How are reimbursement policies influencing the market?
Reimbursement rates vary by insurer and region. Policies favoring biosimilar use may reduce net prices for Lilly and competitors, impacting profitability.
5. Are there innovations that could alter the U-500 insulin market?
Yes, developments such as improved delivery devices, alternative formulations, or long-acting concentrated insulins could impact demand and pricing strategies.
References
- IDF Diabetes Atlas, 2022
- IQVIA, 2022 Market Data
- U.S. FDA, Humulin R U-500 Approval
- Medicare Part D Drug Rebate Insight, 2022
- Eli Lilly corporate reports, 2022
